Articles tagged with Sickle Cell Anemia
Researchers found that hemin injection caused labored breathing, lung injury and rapid death in sickle mice, but not in control mice. Hemopexin was an effective treatment against hemin-induced lung injury.
Researchers at Emory University discovered that hemin injection causes labored breathing and rapid death in sickle mice, but not in control mice. Hemopexin treatment was effective in preventing hemin-induced lung injury. These findings suggest targeting hemin and TLR4 signaling may be a valuable approach for treating acute chest syndrome.
Researchers are working on a new treatment approach to block kidney and lung damage, as well as pain associated with sickle cell disease. The study aims to explore the therapeutic possibilities of endothelin antagonists, which selectively block the endothelin A receptor, and bosentan, which blocks both A and B receptors.
A recent clinical study found that arginine therapy significantly reduces the need for pain medication and lowers pain scores in children with sickle cell disease. The treatment also shows promise as a potential cure for acute pain episodes, with no safety concerns reported.
New research shows hydroxyurea treatment can lower medical costs for children with sickle cell disease by preventing complications and reducing hospitalizations. The study found that children treated with hydroxyurea incurred $3,000 less in medical costs per year compared to those who received standard therapy plus placebo.
A new study led by St. Jude Children's Research Hospital found that a proven drug effective for adults and children with sickle cell anemia reduced hospitalizations and medical costs for young children by 21% annually.
Two Tufts University biomedical graduate students, Seblewongel Asrat and Jennifer Nwankwo, have been awarded HHMI International Student Research Fellowships to study Legionnaires' disease and sickle cell disease. The fellowships provide $43,000 in funding for the first year, with renewal opportunities for two additional years.
Sickle cell anemia is projected to increase by 33% from 2010 to 2050, primarily affecting newborns in sub-Saharan Africa. Implementing basic health interventions could significantly reduce death rates among children under 5 with the condition.
Researchers at UCLA's Eli and Edythe Broad Center have successfully established a foundation for using hematopoietic stem cells to treat sickle cell disease. The breakthrough technique uses anti-sickling genes to create healthy red blood cells that do not sickle, offering a revolutionary alternative to current treatments.
Researchers have successfully used a genetic vector to efficiently transduce bone marrow cells from SCD patients, suggesting a potential treatment method. The study's findings support the use of autologous HSC transplant with genetically modified patient cells to treat sickle cell disease.
Researchers from Brown University have developed computer models that show how different types of red blood cells interact to cause sickle cell crisis. The findings suggest that softer, deformable red blood cells known as SS2 cells start the process by sticking to capillary walls, leading to blockages.
Researchers from La Jolla Institute, Dana-Farber and BloodCenter of Wisconsin are launching Phase II clinical trials to investigate a potential new therapy for reducing sickle cell anemia symptoms. The trial is testing Lexiscan, an existing drug with anti-inflammatory effects.
Scientists need to find better ways to prevent sickling in red blood cells, which impairs oxygen delivery and damages blood vessel walls and organs. Anti-sickling therapies are crucial to reducing damage and improving patient outcomes.
Researchers found diverse consequences of opioid use in patients with sickle cell disease, including biological, psychological, social, and spiritual effects. The study used a grounded theory approach to gather data from 21 African-American adults with SCD, revealing divergent effects on relationships, productivity, mood, and outlook.
Researchers discover that tranylcypromine can reverse the effects of sickle cell disease in mice and human red blood cells. This breakthrough could lead to new treatments for the life-threatening condition, which causes misshapen red blood cells to cause vascular damage and premature death.
Researchers at Duke University Medical Center have developed a way to deploy sickle-shaped red blood cells to fight cancer tumors by exploiting their ability to adhere to and block the blood vessels surrounding hypoxic tumors. The treatment causes tumor cell death through oxidative stress, resulting in delayed tumor growth.
Researchers have found a novel approach to treating hypoxic solid tumors by using sickle-shaped red blood cells to target and destroy tumor cells and surrounding blood vessels. The sickle cells' unique properties allow them to block tumor blood supply and release toxic residues that promote tumor cell death.
Researchers have demonstrated a feasibility study for activating hemoglobin unaffected by the sickle cell mutation using an animal model. The study showed a five- to 20-fold increase in fetal hemoglobin production, paving the way for further research on correcting disease using gene therapy.
Research found that sickle cell patients experience a significant increase in emergency department visits and hospitalizations as they transition from childhood to adulthood. The study, which analyzed data from over 3,200 patients, showed that emergency room visits tripled between ages 15-24.
Research identifies key challenges in providing adequate care to adult SCD patients, including increased reliance on emergency departments and hospitalizations. The studies suggest that targeted interventions can reduce unnecessary medical utilization and promote long-term disease management, ultimately improving health outcomes for th...
Scientists have gained a deeper understanding of how abnormal red blood cells disrupt circulation in sickle cell disease. The study found that hemoglobin abnormalities play a crucial role in occluding vessels, highlighting potential targets for new treatment strategies.
Researchers at Drexel University identified the physical forces in red blood cells and blood vessels underlying the symptoms of sickle cell disease. They found that rigid sickle cells do not get stuck in narrow capillaries, but instead cause partial obstructions in wider vessels.
In a preliminary clinical trial, half-matched bone marrow transplants successfully eliminated sickle cell disease in 11 of 17 patients. The transplants, which used donated marrow from partially matched donors, also improved blood test results and reduced the need for pain medications.
A new study from the University of Michigan found that parents of newborns with sickle cell anemia are less likely to receive genetic counseling than those whose babies are cystic fibrosis carriers. This disparity may be due to physicians' perceptions of the risks associated with each condition.
A targeted educational approach teaches young patients to remain motionless during MRI scans, making the process safer for children with sickle cell disease. The study found that children who completed a brief preparation program were eight times more likely to undergo successful MRI tests without sedation.
Tim Townes receives $20,000 HudsonAlpha Prize for his groundbreaking work on reprogramming cells to treat sickle cell anemia. His research successfully corrects the DNA mutation associated with the disease, producing healthy red blood cells.
Researchers found that regular exercise reduces oxidative stress in individuals with sickle cell trait, increasing antioxidants and nitric oxide levels. This reduction in oxidative stress may help combat the increased morbidity and mortality associated with SCT.
Researchers have developed a simple blood test that can predict which patients with sickle cell disease are at high risk for painful complications. The device measures blood flow through a microfluidic device, allowing doctors to monitor patients and determine the best course of treatment.
Prevention strategies that included ultrasound screening and chronic blood transfusions for children with sickle cell anemia led to a significant decrease in racial disparities in stroke-related deaths. This change occurred after the Stroke Prevention Trial in Sickle Cell Anemia (STOP) was implemented in 1998.
Researchers evaluated the safety and efficacy of hydroxyurea therapy in pediatric patients with SCD and found that continued use of hydroxyurea was associated with lower rates of pain crises, episodic transfusions, and hospital admissions. The studies also showed high acceptance rates for hydroxyurea among families of children with SCD.
A researcher is conducting a study to determine if variations in genes that play a role in metabolizing opioids can help manage sickle cell pain. The goal is to identify patients who are most likely to experience severe pain and target them for aggressive personalized care.
Researchers at the Salk Institute have developed a new gene editing technique that uses patients' own cells to correct genetic mutations in the HBB gene, which causes sickle cell disease. The method repairs the beta-globin gene without introducing harmful genes into cells and appears to be more efficient than traditional techniques.
A recent study has found that nearly a third of children with sickle cell disease have suffered silent strokes, highlighting the need to identify early signs of anemia and high blood pressure. Researchers believe anemia is the key factor contributing to these risk silent strokes.
A study found that children with sickle cell anemia are at risk for silent cerebral infarcts due to low hemoglobin levels, high systolic blood pressure, and male gender. The risk of silent strokes increases by age six, with over 25% of children suffering a stroke by then.
Blood disorders are a significant public health concern, affecting at least 1 million Americans, with limited understanding of their magnitude. A proposed public health framework aims to address the needs of people with rare blood disorders, including early screening, education, and access to care.
Researchers have discovered a key trigger for producing normal red blood cells that could lead to a new treatment for those with sickle cell disease. Increasing the expression of proteins TR2 and TR4 more than doubled the level of fetal hemoglobin produced in sickle cell mice, reducing organ damage.
Scientists have identified a key player in regulating fetal hemoglobin levels, paving the way for new treatments of sickle cell disease. Silencing a specific protein called BCL11A can reactivate fetal hemoglobin production, effectively reversing the condition in adult mice.
Researchers have corrected sickle cell disease in adult mice by activating the production of fetal hemoglobin, a protein that reduces the tendency of sickle hemoglobin to change red blood cells. This approach builds upon earlier studies and offers a new target for future therapies.
A study by researchers at Children's Hospital Boston and Dana-Farber Cancer Institute finds that deactivating the BCL11A protein can correct sickle cell disease in mice by activating fetal hemoglobin. The findings provide strong evidence that BCL11A could be a powerful treatment target for sickle cell disease and related blood disorders.
Researchers at Wake Forest Baptist Medical Center found no association between sickle cell trait and risk of non-diabetic or diabetic end-stage kidney disease. The study contradicts earlier findings that suggested having one copy of the sickle cell gene increased kidney disease risk.
Researchers found that children with malaria are more susceptible to bacteraemia due to the infection itself, not a natural protection from the sickle cell gene. Malaria prevention strategies may also reduce invasive bacterial infections, with an estimated 50% of cases in endemic areas attributed to Plasmodium falciparum.
Researchers will create the largest library of sickle cell disease-specific iPS cell lines to study the disease's genetic context and develop new therapies. The goal is to understand how specific genes behave in different tissues and clarify the mechanisms by which a gene associated with a disease affects tissue biology.
Research reveals most children with SCD do not feel supported by schools in catching up on absences from class. Schools are often divided on whether others should know a pupil has the condition, fearing it may intensify bullying.
Pomalidomide increases production of fetal hemoglobin, boosting red blood cells in patients with sickle cell disease. Unlike hydroxyurea, pomalidomide preserves bone marrow function without suppressing it.
The BABY HUG trial shows that hydroxycarbamide safely prevents early organ damage and reduces common complications of sickle cell disease in very young children. The study's findings suggest that hydroxycarbamide therapy should be considered for all young children with the disease, regardless of symptoms.
A new study shows hydroxyurea reduces acute pain episodes, pneumonia-like illness, hospitalization time, and other symptoms in young patients with sickle cell anemia. The treatment is safe and effective for infant and toddler patients, raising hopes for improving patient quality of life.
A new study found that hydroxyurea significantly reduces pain and complications in young sickle cell anemia patients, including a decrease in chest syndrome and hospitalization. The treatment is safe and effective as a preventive measure for children as young as 9 months.
The ENERCA network has published a series of recommendations for disease management and prevention of complications in children with sickle cell disease. The guidelines recommend universal neonatal screening, prophylaxis with penicillin, and transcranial Doppler scanning to prevent infections and strokes.
Researchers at Instituto Gulbenkian de Ciencia unravel the molecular mechanism of sickle cell trait's protective effect against malaria. Sickle hemoglobin induces heme oxygenase-1, which produces carbon monoxide to protect infected hosts from cerebral malaria.
A study found that young African-American competitive athletes with sickle cell trait are at risk of sudden death, particularly during football training. The study suggests that pre-participation screening is crucial to identify and prevent such deaths.
A new study involving 150 patients with sickle cell disease found that inhaling nitric oxide gas did not improve outcomes, including reducing pain crisis duration or shortening hospital stays. The study's results contradict previous trials suggesting administration of nitric oxide might shorten sickle cell pain crises.
Children with acute anemia are at risk of undetected brain damage due to silent strokes, which can cause poor academic performance and severe cognitive impairments. Regular monitoring and timely transfusion may help prevent permanent brain damage in these children.
Researchers have developed an aptamer that blocks P-selectin receptors, reducing adhesion of sickle-shaped red blood cells and white blood cells. The compound may prevent debilitating pain crises and associated mortality in sickle cell disease, offering a potential new therapy for patients.
Research at St. Jude Children's Research Hospital investigates managing iron overload associated with stroke prevention in young sickle cell patients. Genetic predictors of stroke risk are also being studied, with five common genetic variations validated as markers of increased risk.
Researchers investigate genetic predictors of stroke in pediatric sickle cell disease patients, validating biomarkers and identifying new risk factors. Additionally, a potential breakthrough may inhibit malaria transmission, offering hope for controlling the disease.
The study confirms the 'malaria hypothesis', which suggests that the sickle cell gene provides protection against malaria, allowing it to survive and thrive in areas of intense transmission. The global map shows a significant geographical overlap between the frequency of the sickle cell gene and malaria prevalence.
The Georgia Tech-led Nanomedicine Center plans to pursue a clinically viable gene correction technology for single-gene disorders, including sickle cell disease. The team aims to deliver engineered zinc finger nucleases and DNA correction templates into hematopoietic stem cells to produce healthy red blood cells.
A study of 18 patients with sickle cell disease found that inhaling nitric oxide for four hours reduced pain control compared to standard self-administered morphine. Nitric oxide may help restore hemoglobin's natural shape and charge, addressing the root cause of pain.
A $1.5M NIH grant supports Manu Platt's project to develop models for identifying children at risk of stroke due to sickle cell disease. The goal is to create a mathematical model predicting stroke risk and allow for earlier intervention, improving treatment options.
The NCAA's new sickle cell screening program for college athletes aims to prevent rare complications, but experts warn of hasty implementation and unaddressed consequences. The program may identify 400-500 new cases annually, affecting nearly 170,000 athletes.